To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships
Projects funded by the Research and Innovation Actions (RIA) are collaborative and consist mainly of activities aimed at establishing new knowledge and/or exploring the feasibility of a new or improved technology, product, process, service (or solution).
Le projet EXPERIENCE cherche à utiliser la réalité virtuelle pour améliorer la vie quotidienne en permettant de nouvelles formes d’interaction sociale et d’expression personnelle.
The AROMA project consists in developing the methodology necessary to exploit the full potential of a unique MRI scanner, the future 11.7 Teslas MRI, designed by the CEA and currently being installed at NeuroSpin.
M-ONE will focus on making, from the patented metamaterial technologies developed in M-CUBE, better radio frequency antennas for 7 Tesla MRI. The industrialization of an antenna developed during the M-CUBE project for the 7T of NeuroSpin is also planned thanks to the partnership with the company Multiwave Imaging.
The DECISION consortium aims to identify and optimize new combinatorial therapies to prevent high mortality in patients with decompensated cirrhosis.
FLIX is a radically innovative concept of isotope labeling of molecules with high added value (drugs, biological products, smart materials) with stable isotopes (2H, 13C, 15N) using the properties of new generations of catalysts.
The pan-European research project MICROB-PREDICT aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis and to imagine future personalized therapeutic strategies and diagnostic tools.
AIMS-2-TRIALS, a continuation of the EU-AIMS project and the first European network of clinical trials for autism, aims to improve and personalize treatments for people with Autism Spectrum Disorders (precision medicine).
The R-LiNK project, coordinated by INSERM and involving Edouard Duchesnay and Fawzi Boumezbeur (NeuroSpin), aims to develop and validate a stratified approach to improve the management of patients suffering from bipolar disorder and treated with Lithium salts.
PEVIA - Pan-Ebola Vaccine Innovative Approach - is a collaborative research programme aiming to develop and to bring to the clinics an innovative pan-Ebola vaccine, safe and effective against multiple Ebola virus strains and ease to produce and deploy in endemic regions.
ABACUS, coordinated by CEA Cadarache, aims to develop a business- and technology-driven algae biorefinery, bringing innovative, high-value-added algae-based ingredients (terpenes and terpenoids) to market.
M-CUBE aims to change the paradigm of high-field and ultra-high-field MRI antennas to provide a better view of the human body and allow early detection of diseases.
ABIRISK Project aims to provide an integrated approach to anti-drug (AD) immunization, bringing together, a large network of clinicians from various specialties with broad experience in the care of patients treated with various type of biopharmaceuticals products and developing AD antibodies, biologists familiar with the immune monitoring of patients, scientists specialized in the mechanisms of immunogenicity, methodologists and biostatisticians.
EU-AIMS aims to identify markers of autism that would allow earlier and more accurate diagnosis and prognosis, and the development of new therapies.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.